Sarmiento Doncel Samuel, Peláez Ronald Guillermo, Lapunzina Pablo, Corrales-Medina Fernando F, Díaz Mosquera Gina Alejandra, Bonanad Santiago, Cortes Javier Mauricio, Cazalla Mario, Gallego Natalia, Querol-Giner Felipe, Tenorio Jair, López Guerrero José A
Integral Solutions SD SAS, Integral Solutions Research, Bogota 110121, Colombia.
Life Sciences and Health Research Group, Graduates School, CES University, Medellin 050021, Colombia.
Life (Basel). 2024 Aug 21;14(8):1041. doi: 10.3390/life14081041.
Hemophilia A is an X-linked disorder characterized by quantitative deficiency of coagulation factor VIII (FVIII) caused by pathogenic variants in the factor 8 () gene. Our study's primary objective was to identify genetic variants within the exonic region of in 50 Colombian male participants with severe hemophilia A (HA). Whole-exome sequencing and bioinformatics analyses were performed, and bivariate analysis was used to evaluate the relationship between identified variants, disease severity, and inhibitor risk formation. Out of the 50 participants, 21 were found to have 17 different pathogenic variants (var). It was found that 70% (var = 12) of them were premature truncation variants (nonsense, frameshift), 17.6% (var = 3) were missense mutations, and 11.7% (var = 2) were splice-site variants. Interestingly, 35% (var = 6) of the identified variants have not been previously reported in the literature. All patients with a history of positive inhibitors (n = 4) were found to have high-impact genetic variants (nonsense and frameshift). When investigating the relationship between variant location (heavy versus light chain) and specific inhibitor risk, 75% (n = 3) of the inhibitor participants were found to have variants located in the light chain ( = 0.075), suggesting that conserved domains are associated with higher inhibitor risk. In summary, we identified genetic variants within the that can possibly influence inhibitor development in Colombian patients with severe HA. Our results provide a basis for future studies and the development of further personalized treatment strategies in this population.
甲型血友病是一种X连锁疾病,其特征是由凝血因子8(F8)基因的致病变异导致凝血因子VIII(FVIII)定量缺乏。我们研究的主要目的是在50名患有严重甲型血友病(HA)的哥伦比亚男性参与者中鉴定F8外显子区域内的基因变异。进行了全外显子测序和生物信息学分析,并使用双变量分析来评估鉴定出的变异、疾病严重程度和抑制剂风险形成之间的关系。在50名参与者中,发现21人有17种不同的致病变异(var)。发现其中70%(var = 12)是过早截断变异(无义、移码),17.6%(var = 3)是错义突变,11.7%(var = 2)是剪接位点变异。有趣的是,35%(var = 6)的鉴定变异此前未在文献中报道。所有有阳性抑制剂病史的患者(n = 4)均发现有高影响基因变异(无义、移码)。在研究变异位置(重链与轻链)与特定抑制剂风险之间的关系时,发现75%(n = 3)的抑制剂参与者的变异位于轻链(P = 0.075),这表明保守结构域与更高的抑制剂风险相关。总之,我们在F8中鉴定出可能影响哥伦比亚严重HA患者抑制剂形成的基因变异。我们的结果为该人群未来的研究和进一步个性化治疗策略的开发提供了基础。